VDYNE Receives FDA Approval for Tricuspid Valve Replacement Trial

The company's Transcatheter Tricuspid Valve Replacement system will undergo pivotal clinical testing.

Apr. 2, 2026 at 6:22am

Got story updates? Submit your updates here. ›

VDYNE, a medical device company developing transcatheter valve replacement technologies, announced that the U.S. Food & Drug Administration (FDA) has approved an investigational device exemption (IDE) for the company's pivotal clinical trial evaluating its Transcatheter Tricuspid Valve Replacement (TTVR) system. The IDE approval enables the initiation of a U.S. pivotal study at leading clinical centers to evaluate the safety and effectiveness of the VDYNE system in patients with severe tricuspid regurgitation.

Why it matters

Significant unmet clinical needs exist in the treatment of tricuspid regurgitation, with 1.5 million people in the US suffering from the condition and a small percentage eligible for surgical treatment. Severe tricuspid regurgitation is linked to poor prognosis and high mortality, yet current treatment options remain extremely limited. VDYNE's TTVR system is designed as a minimally invasive solution to address the complexities of tricuspid valve anatomy and disease.

The details

VDYNE's TTVR system has been used globally through clinical studies and compassionate use since its first-in-human use in November 2023, providing important insights into procedural performance and clinical outcomes. The company is now focused on disciplined clinical execution and partnering with leading investigators to generate high-quality data that advances the field and improves patient care.

  • The FDA approved VDYNE's IDE for the TRIVITA1 pivotal trial on April 2, 2026.
  • VDYNE's TTVR system was first used in a human patient in November 2023.

The players

VDYNE, Inc.

A privately held medical device company focused on developing innovative transcatheter valve replacement technologies for the treatment of tricuspid regurgitation. Headquartered in Maple Grove, Minnesota, VDYNE is dedicated to transforming care for patients suffering from right heart valve disease.

Mike Buck

Chief Executive Officer of VDYNE, Inc.

Got photos? Submit your photos here. ›

What they’re saying

“This is a defining milestone for VDYNE and an important step toward bringing a much-needed therapy to patients with severe tricuspid regurgitation.”

— Mike Buck, Chief Executive Officer

What’s next

The judge in the case will decide on Tuesday whether or not to allow Walker Reed Quinn out on bail.

The takeaway

VDYNE's FDA-approved pivotal trial for its Transcatheter Tricuspid Valve Replacement system represents a significant advancement in addressing the unmet clinical needs and high mortality rates associated with severe tricuspid regurgitation, a condition that currently has limited treatment options.